Marinus Pharmaceuticals, Inc. MRNS
At closeFeb 10, 2025, 4:00 PM EST
52-week range unavailable
- YTD
- +2.78%
- 1 year
- -94.49%
- Market cap
- 13.13M
- Revenue (ttm)
- 30.26M
- Shares out
- 55.19M
- Forward P/E
- -0.34
- YTD return
- +2.78%
- 1-year return
- -94.49%
- Volume
- 1.10M
- Open
- 0.5492
- Previous close
- 0.55
- Day's range
- 0.5492 – 0.55
- Beta
- 1.26
- Price target
- 1.47 (+166.7%)
2Y -1.1300 (-67.26%)
Key statistics
- Enterprise value
- 50.22M
- PEG ratio
- 0.00
- Price / sales
- 0.43
- Price / book
- 0.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 32.50%
- Free cash flow
- -66.13M
- Total cash
- 64.68M
- Total debt
- 95.89M
- Return on equity
- -2986.55%
- Short % of float
- 10.32%
- 50-day average
- 0.5705
- 200-day average
- 2.12
Analyst view
- Target (low)
- 0.30
- Target (mean)
- 1.47
- Target (high)
- 3.00
- Strong buy0
- Buy2
- Hold7
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.285.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.44 | -0.42 | +0.02 | +4.55% |
| Aug 13, 2024 | Jun 1, 2024 | -0.59 | -0.60 | -0.01 | -1.69% |
| May 8, 2024 | Mar 1, 2024 | -0.68 | -0.68 | 0.00 | 0.00% |
| Mar 5, 2024 | Dec 1, 2023 | -0.64 | -0.74 | -0.10 | -15.63% |
| Nov 7, 2023 | Sep 1, 2023 | -0.67 | -0.61 | +0.06 | +8.96% |
| Aug 10, 2023 | Jun 1, 2023 | -0.76 | -0.61 | +0.15 | +19.74% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Oct 25, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 25, 2024 | TD Cowen | down | Buy | Hold |
| Oct 25, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 25, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- marinuspharma.com
News
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm 
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm 
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know 
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders 
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders 
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. 
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates 
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on MRNS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRAUNSTEIN SCOTT N. | Chief Executive Officer | Sale | Aug 4, 2024 | 298,667 |
| EZICKSON ELAN Z | Director | Stock Award(Grant) | Jun 17, 2024 | 12,500 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | Jun 17, 2024 | 12,926 |
| HULIHAN JOSEPH M.D. | Officer | Sale | Aug 4, 2024 | 72,725 |
| MANNING MARTHA E | General Counsel | Sale | Aug 4, 2024 | 60,263 |
| MAYLEBEN TIMOTHY M | Director | Stock Gift | Oct 9, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.19% | 5,073,913 | 1.21M | Sep 29, 2024 |
| Franklin Resources, Inc. | 8.54% | 4,713,014 | 1.12M | Sep 29, 2024 |
| Tang Capital Management, LLC | 8.52% | 4,700,000 | 1.12M | Sep 29, 2024 |
| Sofinnova Investments, Inc. | 7.95% | 4,386,177 | 1.04M | Sep 29, 2024 |
| Vanguard Group Inc | 5.08% | 2,802,965 | 667.11K | Sep 29, 2024 |
| Bain Capital Life Sciences Investors, LLC | 4.88% | 2,693,380 | 641.02K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.14% | 1,730,190 | 411.79K | Sep 29, 2024 |
| abrdn Healthcare Investors | 2.78% | 1,532,400 | 364.71K | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.18% | 1,200,781 | 285.79K | Jul 30, 2024 |
| abrdn Life Sciences Investors | 2.04% | 1,126,127 | 268.02K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.47% | 811,000 | 193.02K | Sep 29, 2024 |
| iShares Biotechnology ETF | 0.63% | 347,160 | 82.62K | Oct 30, 2024 |